Brookline Capital initiates Cardiol Therapeutics stock with Buy rating
PositiveFinancial Markets

Brookline Capital has initiated coverage of Cardiol Therapeutics with a 'Buy' rating, signaling strong confidence in the company's potential for growth. This endorsement is significant as it may attract more investors and boost the stock's performance, reflecting optimism about Cardiol's future prospects in the healthcare sector.
— Curated by the World Pulse Now AI Editorial System